Investor Relations

Press Release

June 9, 2020

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial

More
June 2, 2020

Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

More
May 7, 2020

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020

More
May 4, 2020

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2020

More
April 27, 2020

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial

More
April 13, 2020

Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure

More
April 9, 2020

Amphastar Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

More
March 12, 2020

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019

More
March 5, 2020

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12th, 2020

More
February 27, 2020

Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL

More